 |
 | Journal Of Clinical Oncology Publishes Study Of Cephalon Me |  |
|
RSS FEED
|
|
Cephalon, Inc. (Nasdaq: CEPH) announced that in a phase 2 study published online in the Journal of Clinical Oncology, 92 percent of patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma (NHL) responded to treatment with TREANDA(R) (bendamustine hydrochloride) for Injection plus rituximab. This combination study is one of three studies in patients with NHL that Cephalon submitted in December 2007 to the U.S.
Read more... |
|||||||||||
|
|||||||||||||
 |
 | Journal Of Clinical Oncology Publishes Study Of Cephalon Me | |
|
||
|
|
|
Site Map
|
Sitemap |